Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.[1] It was founded in 2008 by Osman Kibar.[2]
Samumed's products in development target novel components of the Wnt signaling pathway.[3][4][5] The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced.[4][6]